Clinical Trial Update: Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 safety study of a radiolabeled antibody (7E11) in patients with progressive hormone-refractory metastatic prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ProstaScint (capromab pendetide)

Snippet

Sponsor: Cytogen Corporation | Conditions: Metastatic Prostate Cancer | Phase 1 | Status: UNKNOWN